

Lead Product(s) : Methylhexaneamine
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Sponsor : University of Tennessee | USP Labs, Inc.
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharmacokinetic Effects of Oral DMAA
Details : 1,3-dimethylamylamine is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 11, 2013
Lead Product(s) : Methylhexaneamine
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Sponsor : University of Tennessee | USP Labs, Inc.
Deal Size : Inapplicable
Deal Type : Inapplicable
